Twist Bioscience (NASDAQ:TWST) Sets New 52-Week High at $56.20

Twist Bioscience Co. (NASDAQ:TWST)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $56.20 and last traded at $55.97, with a volume of 187502 shares traded. The stock had previously closed at $53.44.

Analyst Upgrades and Downgrades

TWST has been the topic of several research analyst reports. Barclays upped their price objective on Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Scotiabank upped their price objective on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. TD Cowen raised their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Finally, The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience has a consensus rating of “Buy” and an average target price of $49.75.

Twist Bioscience Trading Up 4.0 %

The company has a market capitalization of $3.24 billion, a PE ratio of -16.18 and a beta of 1.80. The firm has a fifty day moving average of $47.33 and a two-hundred day moving average of $39.32.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The business had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.06) EPS. On average, equities analysts expect that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 4,163 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now owns 509,986 shares in the company, valued at approximately $18,935,780.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Twist Bioscience news, COO Patrick John Finn sold 2,174 shares of Twist Bioscience stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the sale, the chief operating officer now directly owns 176,206 shares in the company, valued at approximately $5,307,324.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 4,163 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now owns 509,986 shares of the company’s stock, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. Insiders have sold 19,570 shares of company stock valued at $827,162 over the last ninety days. Insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. QRG Capital Management Inc. lifted its holdings in shares of Twist Bioscience by 9.1% in the 2nd quarter. QRG Capital Management Inc. now owns 59,443 shares of the company’s stock worth $2,929,000 after acquiring an additional 4,981 shares during the last quarter. CWM LLC raised its position in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after purchasing an additional 524 shares during the period. GAMMA Investing LLC boosted its position in shares of Twist Bioscience by 1,896.8% during the second quarter. GAMMA Investing LLC now owns 3,754 shares of the company’s stock valued at $185,000 after buying an additional 3,566 shares during the period. Castleark Management LLC grew its stake in shares of Twist Bioscience by 11.8% during the first quarter. Castleark Management LLC now owns 146,630 shares of the company’s stock valued at $5,031,000 after buying an additional 15,470 shares during the last quarter. Finally, Bayesian Capital Management LP lifted its stake in shares of Twist Bioscience by 42.7% during the 1st quarter. Bayesian Capital Management LP now owns 14,546 shares of the company’s stock worth $499,000 after acquiring an additional 4,352 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.